Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.

Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

Мобильная версия

Регистрация Забыли пароль?

Журнал "Гастроэнтерология" Том 52, №3, 2018

Вернуться к номеру

Зміни рівнів простагландинів у сироватці крові в пацієнтів iз гастроезофагеальною рефлюксною хворобою на фоні цукрового діабету ІІ типу

Зміни рівнів простагландинів у сироватці крові в пацієнтів iз гастроезофагеальною рефлюксною хворобою на фоні цукрового діабету ІІ типу

Авторы: Ye.S. Sirchak, M.P. Stan
SHEI “Uzhhorod National University”, Uzhhorod, Ukraine

Рубрики: Гастроэнтерология

Разделы: Клинические исследования

Версия для печати


Резюме

Актуальність. В основі ураження органів травлення в пацієнтів із цукровим діабетом (ЦД) лежать декілька механізмів: дисфункція вегетативної нервової системи, ангіо­патія, дисрегуляція секреції та інактивація гормонів і інкрементів. Мета дослідження: вивчити особливості зміни рівня простагландинів (Pg) (І2 та F2α) в сироватці крові в пацієнтів iз гастроезофагеальною рефлюксною хворобою (ГЕРХ) на фоні ЦД ІІ типу залежно від порушення індексу маси тіла. Матеріали та методи. Обстежено 54 пацієнти з ЦД ІІ типу та ГЕРХ (І група). У групу порівняння увійшло 22 пацієнти з ГЕРХ (ІІ група). В обстежених хворих визначали показники Pg F2α та 6-кето-простагландину F1α (простациклін крові — Pg I2) в сироватці крові. Результати. Встановлено підвищення рівнів простагландинів в обох групах пацієнтів, але більш виражені зміни спостерігаються в І групi. Звертає на себе увагу більш суттєве зростання концентрації Pg I2 порівняно з показником Pg F2α, особливо в пацієнтів iз ГЕРХ на фоні ЦД ІІ типу (в 3,4 раза проти 2,1 раза в І групi). У пацієнтів iз ГЕРХ встановлено зростання рівня Pg I2 в 2,2 раза, а Pg F2α — лише в 1,6 раза. При поєднанні декількох патологічних станів (ЦД ІІ типу, ГЕРХ, порушення індексу маси тіла) спостерігається більш виражене підвищення концентрації саме простацикліну, що також залежить від тривалості захворювання. Висновки. У пацієнтів iз ГЕРХ встановлено збiльшення рівня простагландинів F2α та I2 в сироватці крові. Поєднання ГЕРХ та ЦД ІІ типу супроводжується більш вираженим зростанням концентрації простагландинів, особливо Pg I2, в сироватці крові. Встановлено залежність між тривалістю ЦД ІІ типу, надмірною вагою тіла та динамікою рівня Pg I2 в сироватці крові в пацієнтів iз ГЕРХ на фоні ЦД ІІ типу.

Актуальность. В основе поражения органов пищеварения у пациентов с сахарным диабетом (СД) лежат несколько механизмов: дисфункция вегетативной нервной системы, ангиопатия, дисрегуляция секреции и инактивация гормонов и инкрементов. Цель работы: изучить особенности изменения уровня простагландинов (Pg) (I2 и F2α) в сыворотке крови у пациентов с гастроэзофагеальной рефлюксной болезнью (ГЭРБ) на фоне СД II типа в зависимости от нарушения индекса массы тела. Материалы и методы. Обследовано 54 пациента с СД II типа и ГЭРБ (I группа). В группу сравнения вошло 22 пациента с ГЭРБ (II группа). У обследованных пациентов определяли показатели Pg F2α и 6-кето-простагландина F1α (простациклин крови — Pg I2) в сыворотке крови. Результаты. Установлено повышение уровня простагландинов в обеих группах пациентов, но более выраженные изменения наблюдаются в I группе. Обращает на себя внимание более существенное увеличение концентрации Pg I2 по сравнению с показателем Pg F2α, особенно у пациентов с ГЭРБ на фоне СД II типа (в 3,4 раза против 2,1 раза в I группе). У пациентов с ГЭРБ установлено повышение уровня Pg I2 в 2,2 раза, а Pg F2α — только в 1,6 раза. При сочетании нескольких патологических состояний (СД II типа, ГЭРБ, нарушение индекса массы тела) наблюдается более выраженное увеличение концентрации именно простациклина, что также зависит от продолжительности заболевания. Выводы. У пациентов с ГЭРБ установлено повышение уровня простагландинов F2α и I2 в сыворотке крови. Сочетание ГЭРБ и СД II типа сопровождается более выраженным увеличением концентрации простагландинов, особенно Pg I2, в сыворотке крови. Установлена зависимость между продолжительностью СД II типа, избыточной массой тела и динамикой уровня простагландина Pg I2 в сыворотке крови у пациентов с ГЭРБ на фоне СД II типа.

Background. Digestive organ damage in patients with diabetes mellitus (DM) is based on several mechanisms: autonomic nervous system dysfunction, angiopathy, dysregulation of secretion and inactivation of hormones and increments. The purpose was to study the features of changes in prostaglandin (Pg) levels (I2 and F2α) in the blood serum of patients with gastroesophageal reflux disease (GERD) on the background of type 2 DM depending on the body mass index violation. Materials and methods. The study involved 54 patients with type 2 DM and GERD (group I). The comparison group included 22 patients with GERD (group II). The patients had their blood serum examined and indicators of Pg F2α and 6-keto-prostaglandin F1α (blood prostacyclin — Pg I2) determined. Results. Increased levels of prostaglandins in both groups of patients were detected, but more significant changes were observed in group I. Attention is called to a more significant increase in Pg I2 concentration compared with Pg F2α, especially in patients with GERD on the background of type 2 DM (3.4 times compared with 2.1 times in group I). Patients with GERD revealed the increased levels of Pg I2 by 2.2 times, while Pg F2α is only 1.6 times higher. In the combination of several pathological states (type 2 DM, GERD, increased body mass index), there is a more significant increase in the concentration of prostacyclin, which also depends on the duration of the disease. Conclusions. In patients with GERD, an increase in the levels of prostaglandins F2α and I2 in the blood serum has been detected. The combination of GERD and type 2 DM is accompanied by a more significant increase in the concentration of prostaglandins, especially Pg I2, in the blood serum. The correlation was established between the duration of type 2 DM mellitus, excessive body weight and the dynamics of Pg I2 level in the blood serum of patients with GERD on the background of type 2 diabetes mellitus.


Ключевые слова

гастроезофагеальна рефлюксна хвороба; цукровий діабет ІІ типу; простагландини

гастроэзофагеальная рефлюксная болезнь; сахарный диабет II типа; простагландины

gastroesophageal reflux disease; type 2 diabetes mellitus; prostaglandins

doi: http://dx.doi.org/10.22141/2308-2097.52.3.2018.141840

Introduction

Gastroesophageal reflux disease (GERD) is a topical problem of modern gastroenterology due to its high prevalence, the development of severe complications, the need for long-term therapy, and a significant deterioration in the quality of life of patients [1–3].
As it is known, the etiopathogenesis of GERD is based on the imbalance between the protective (barrier function of the lower esophageal sphincter, effective esophageal clea–rance, normal resistance of the esophageal mucosa) and aggressive factors (hydrochloric acid, pepsin, bile, pancreatic enzymes, etc.) [4, 5]. The emergence of pathological gastroesophageal reflux is also promoted by an increase in the intraabdominal (obesity, pregnancy) and intragastric pressure (gastric stasis, duodenostasis of functional or organic nature) [1].
In clinical practice, 75 % of patients with diabetes mellitus (DM) have symptoms of damage to the gastrointestinal tract, with almost all sections of the digestive tract being affected [6].
Digestive organ damage in patients with DM is based on several mechanisms: autonomic nervous system dysfunction, dysregulation of secretion and inactivation of hormones and increments, as well as electrolyte disorders associated with uremia and ketoacidosis [7]. Many hormones and biologically active substances in the body (estrogen, progesterone, prostaglandins, somatostatin, cholecystokinin, etc.) affect the tension of the lower esophageal sphincter [8].
Consequently, in diabetes mellitus, the changes in regulatory substances due to metabolic disorders combined with the changes in the neurotropic control of the lower esophageal sphincter on the background of diabetic autonomic neuropathy creates conditions for the contact of aggressive contents in the stomach and duodenum with esophageal mucosa and leads to the emergence of clinical manifestations of GERD. Studying the features of changes in regulatory biologically active substances in patients with type 2 DM can reveal new pathogenetic mechanisms for the formation of organ damage in the digestive system, including the esophagus, in these persons.
Purpose of the research was to study the features of changes in serum prostaglandin (I2 and F2α ) levels in patients with GERD on the background of type 2 diabetes mellitus depending on the body mass index violation.
Scientific research is a fragment of a state-funded topic of the department of surgical diseases and the department of propaedeutics of internal diseases of the medical faculty of the SHEI “UzhNU” No. 815 “Mechanisms of complications formation in liver and pancreatic diseases, methods of their treatment and preventive measures”, state registration number: 0115U001103.

Materials and methods

At the premises of the department of propaedeutics of internal diseases (gastroenterological and endocrinological departments of A. Novak Transcarpathian Regional Clinical Hospital) of the medical faculty of the SHEI “UzhNU”, 54 patients with type 2 DM and GERD were examined in 2016–2017. Among patients with type 2 DM, there were 30 males (55.6 %) and 24 females (44.4 %). Their average age was (48.6 ± 6.2) years. These patients were included in the main study group (group I).
The comparison group consisted of 22 patients with GERD (group II) — 12 males (54.5 %) and 10 females (45.5 %). Their average age was (48.3 ± 5.7) years. The control group included 20 apparently healthy individuals (12 males (60.0 %), 8 females (40.0 %)), their average age was (47.6 ± 5.8) years.
All studies were conducted with patient’s consent, and the methodology of conducting the study complied with 1964 Declaration of Helsinki and its 2013 revision [9, 10].
Patients underwent general clinical examination according to local protocols. Anthropometric, general clinical, laboratory and instrumental methods of investigation were used. In the verification of the diagnosis, attention was paid to the nature of the complaints, anamnesis of the disease.
During the anthropometric examination, the body mass index (BMI), waist circumference (WC), hip circumfe–rence (HC) were measured, and the waist/hip index (WHI =
= WC/HC) was calculated. According to the obtained data, in compliance to World Health Organization recommendations, patients were distributed by their BMI: BMI 16.0 and less corresponded to the expressed deficient body weight; 16.0–18.5 — insufficient body weight; 18.5–24.9 — normal weight; 25.0–29.9 — excessive weight; 30.0–34.9 — class I obesity; 35.0–39.9 — class II obesity; 40.0 and more — class III obesity (morbid obesity) [11].
The diagnosis of type 2 DM has been made according to the International Diabetes Federation (2005) guidelines and to the criteria of the unified clinical protocol (Ministry of Health order No. 1118 issued 21.12.2012) [12, 13]. The severity of type 2 DM has been evaluated according to the level of glycated hemoglobin (%), which was determined by a chromogenic assay on the Sysmex 560 analyzer (Japan) using Siemens reagents. The patients also had electrocardiographic examination.
GERD was diagnosed according to the criteria of the unified clinical protocol (Ministry of Health order No. 943 issued 31.10.2013) taking into account patients’ complaints, endoscopic examination data, etc. [14]. In order to prove the diagnosis, the patients underwent esophagogastroduodenoscopy conducted with the help of endoscopic equipment — Pentax EPM-3300 video processor and Pentax E-2430 elastic fiberscopes GIF-K20. The patients also had daily pH-monitoring (according to prof. V.N. Chernobrovov).
All patients had their serum 8-iso-prostaglandin F2α (Pg F2α ) and 6-keto-prostaglandin F1α (blood prostacyclin — Pg I2 ) levels examined using immunoassay analysis with the help of Enzo Life Sciences test systems (USA).
The criteria for patients’ inclusion into the study were: type 2 diabetes mellitus, erosive form of GERD.
The criteria for patients’ exclusion from the study: type 1 diabetes mellitus, functional or organic diseases of the esophagus, stomach and duodenum, non-erosive form of GERD.
Results of the patients’ examination were analyzed and processed by means of computer program Statistica 10.0 (StatSoft Inc., USA) using parametric and non-parametric methods.

Results

In all patients in group І (GERD and type 2 DM), an excessive body weight or obesity of varying degrees were found while analyzing anthropometric measurements. The vast majority of patients (54.5 %) in group II (GERD) had normal body weight, and only 36.4 % — excessive body weight (Table 1).
The determination of prostaglandin F2α  and prostacyclin (Pg I2 ) serum levels in patients of both groups and healthy individuals was performed. The results are presented in –Table 2.
Increased levels of prostaglandins were detected in both groups of the examined patients, but more significant changes were observed in group I (combination of type 2 DM and GERD). Attention is called to a more significant increase in Pg I2 concentration compared to Pg F2α in the blood serum, especially in patients with GERD on the background of type 2 DM (3.4 times vs 2.1 times in group I). Levels of Pg I2 in patients with GERD were increased by 2.2 times, while Pg F2α is only 1.6 times higher.
Changes in prostaglandin levels in the examined patients were evaluated depending on the violation of BMI (Table 3).
A more significant increase of Pg I2 was found in the blood serum of patients with GERD on the background of type 2 DM and excessive body weight, as compared to the patients of the same group with class I and II obesity. While assessing the changes in serum Pg F2α  in patients of group I, the same tendency was not established. In patients with GERD, the lowest concentration of Pg I2 in the blood serum was detected in those with normal body weight, and in persons with excessive weight and class I obesity, there was no significant difference between these indices.
According to the results of the analysis of anamnestic data, as well as the data of preliminary medical documentation (extracts from the clinical record, records in outpatient cards), the duration of the disease in the examined patients was evaluated (Table 4).
In patients with obesity, the clinical signs of GERD are detected almost simultaneously with the diagnosis of type 2 DM. In patients of the same group with excessive body weight, GERD is diagnosed only 5–5.5 years after the diagnosis of type 2 DM.

Discussion

Digestive organ damage in case of type 2 DM, including the upper gastrointestinal tract, is actively discussed in the professional literature. Scientific research is aimed at determining the prevalence of GERD in patients with type 2 DM, as well as studying various factors underlying the formation of GERD in these patients. H. Sun et al. (2014) indicate a high prevalence of GERD among patients with type 2 DM, while the relationship between diabetic neuropathy, metabolic disorders on the background of diabetes and the occurrence of clinical manifestations of GERD was not revealed according to their data [15]. On the contrary, Korean scientists (S.D. Lee et al., 2014) argue that diabetic neuropathy plays an important role in the formation of GERD with type 2 DM, especially in the development of erosive esophagitis (31.5 vs 10.5 %, P = 0.022) [6]. The study of J.O. Ha et al. (2016) has also proven the role of diabetic neuropathy in the development of GERD in type 2 DM, moreover, the correlation has been established between GERD and the duration of diabetes, as well as the age of patients [16].
It should be noted that the performed research is mainly aimed at identifying the relationship between diabetic neuropathy and the formation of GERD with type 2 DM. We have not found any scientific works that discuss the role of prostaglandins in patients with the combination of GERD and type 2 DM.
The analyzed publications are devoted to the study of prostaglandins, separately in type 2 DM and separately in case of damage to the upper gastrointestinal tract, inclu–ding GERD. K. Takeuchi (2010) highlights the role of prostaglandins, predominantly type E, in GERD and chronic gastritis. At the same time, the authors have proven that Pg E2 protects the esophagus from acid reflux and provides cytoprotection of the stomach [17]. In his review paper, V.A. Chernyshov (2013) discusses changes in the expression of 8-iso-prostaglandin F2α in the daily urine depending on the performed hypoglycemic therapy in patients with type 2 DM [18].
The research of V.O. Serhienko et al. (2017) is aimed at studying the influence of combination therapy consisting in the use of omega-3 polyunsaturated fatty acids and statins on the lipidogram dynamics and the levels of various biologically active substances, including 6-keto-prostaglandin F1α, in patients with type 2 DM associated with diabetic cardiovascular autonomic neuropathy. In this case, the initially increased levels of 6-keto-prostaglandin F1α were detected in these patients [19]. E.H. Dorosh and N.A. Kravchun (2013) determined the level of 8-iso-prostaglandin in patients with type 2 DM associated with nonalcoholic fatty liver disease (NAFLD). The results of their studies indicate an increase in 8-iso-prostaglandin level to (386.3 ± 42.2) pg/ml in patients with the combined pathology (type 2 DM and NAFLD), which is significantly higher compared to the patients with type 2 diabetes without NAFLD ((202.2 ± 84.5) pg/ml, p < 0.05) and 10 times higher compared to healthy persons ((38.8 ± 6.0) pg/ml, p < 0.001). On the basis of their research, it was also concluded that patients with type 2 DM and associated pathology (type 2 DM and NAFLD) have excessive weight and obesity of varying degrees [20].
We have studied the levels of F2α and I2 prostaglandins, which have a divergent effect on the body, namely: Pg F2α exhibits a constrictive effect, while prostaglandin І2, on the contrary, has relaxing properties. According to the results of our study, increased serum levels of prostaglandins F2α and I2 in patients with GERD were determined. At the same time, more significant changes were detected in the combined pathology (GERD and type 2 DM).
When characterizing the changes in prostaglandins by classes, a predominant increase in serum prostacyclin was detected. In patients with the combination of GERD and type 2 DM, it is 1.5 times higher than that in patients with GERD not suffering from type 2 DM.
The obtained data also indicate that in case of combination of several pathological states (type 2 DM, GERD, increased BMI), a more significant increase is observed in the concentration of prostacyclin, and Pg І2 depends on the disease duration.
High level of prostaglandin, which has a relaxing effect on smooth muscles, including the digestive system, suggests its influence on the formation of GERD, especially on the background of type 2 DM. It is plausible that the loss of physiological balance between prostaglandins, which have opposite effects on the internal organs on the background of metabolic disorders in obesity and diabetes, may be conside–red as one of the components affecting the lower esophageal sphincter, leading to its relaxation and the formation of GERD manifestations. The obtained data require further investigation, analysis of changes in prostaglandins in type 2 DM and their probable effect on the formation of GERD in these patients.

Conclusions

1. In patients with GERD, an increase in the levels of prostaglandins F2α and I2 in the blood serum was detected (up to (119.68 ± 9.26) pg/ml and (115.22 ± 7.84) pg/ml, respectively).
2. The combination of GERD and type 2 DM is accompanied by a more significant increase in serum concentration of prostaglandins, especially I2 (up to (176.94 ± 8.41) pg/ml as compared to the control group — (52.17 ± 6.44) pg/ml; p < 0.01), than in patients with GERD without type 2 DM.
3. In patients with GERD on the background of type 2 DM, the maximum concentration of prostacyclin in the blood serum ((192.61 ± 10.54) pg/ml) was detected in excessive body weight, as well as of prostaglandin F2α ((165.41 ± 6.89) pg/ml) — in patients with class II obesity.
Conflicts of interests. Authors declare no conflicts of interests that might be construed to influence the results or interpretation of their manuscript.
Information on contribution of each author:
Ye.S. Sirchak — concept and design of the research, analysis of the data; M.P. Stan — collection and processing of materials, writing the text.

Список литературы

1. Маев И.В. Гастроэзофагеальная рефлюксная болезнь (обзор материалов XVII Российской гастроэнтерологической недели, 10–12 октября 2011 г., Москва) / И.В. Маев, Г.Л. Юренев, Г.А. Бусарова // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2012. — № 5. — С. 13-23.
2. Влияние психокоррекции на характер течения заболевания и качество жизни больных гастроэзофагеальной рефлюксной болезнью, бронхиальной астмой и при их сочетании / И.В. Маев, Г.Л. Юренев, Д.Т. Дичева и др. // Медицинский cовет. — 2012. — № 6. — С. 56-63.
3. Katz P.O. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease / P.O. Katz, L.B. Gerson, M.F. Vela // Am. J. Gastroenterol. — 2013. — № 108. — Р. 308-328.
4. Esophageal chemical clearance is impaired in gastro-esopha–geal reflux disease — а 24-h impedance-pH monitoring assessment / M. Frazzoni, R. Manta, V.G. Mirante et al. // Neurogastroenterol. Motil. — 2013. — № 25. — Р. 399-406. — e295.
5. Драгомирецкая Н.В. Пути совершенствования терапии ГЭРБ / Н.В. Драгомирецкая // Здоров’я України. Тематичний номер «Гастроентерологія. Гепатологія. Колопроктологія». — 2016. — № 4 (42). — С. 21.
6. Gastroesophageal Reflux Disease in Type II Diabetes Mellitus With or Without Peripheral Neuropathy / S.D. Lee, B. Keum, H.J. Chun, Y.T. Bak // J. Neurogastroenterol. Motil. — 2011. — № 17 (3). — Р. 274-278.
7. Новейшие технологии в теоретической и практической гастроэнтерологии. По итогам IV научной сессии ГУ «Институт гастроэнтерологии НАМН Украины» / Ю.М. Степанов, М.П. Захараш, И.Н. Скрыпник, Е.Ю. Губская // Здоров’я України. — 2016. — № 13–14 (386–387). — С. 20-21.
8. Кушнир И.Э. ГЭРБ у пациентов с ожирением: патофизио–логические механизмы развития, особенности течения и подходы к терапии / И.Э. Кушнир // Здоров’я України. Тематичний номер «Гастроентерологія. Гепатологія. Колопроктологія». — 2013. — № 3 (29). — С. 70-71.
9. Karmela K.J. 7th Revision of the Declaration of Helsinki: Good News for the Transparency of Clinical Trials / K.J. Karmela, T. Lemmenens // Croat. Med. J. — 2009. — № 50 (2). — P. 105-110.
10. Emanuel E.Y. The Eighth Revision of the Declaration of Helsinki: What Should be Done? // https://www.wma.net/wp-content/uploads/2017/01/Presentation_Emanuel.pdf
11. WHO: Global Database on Body Mass Index // http://apps.who.int/bmi/index.jsp?introPage=intro_3.html
12. Цукровий діабет 2 типу / М.К. Хобзей, М.В. Гульчій, А.В. Степаненко та ін. // Уніфікований клінічний протокол первинної та вторинної (спеціалізованої) медичної допомоги. — К., 2012. — 118 с.
13. Цукровий діабет 2 типу / М.В. Гульчій, Л.Ф. Матюха, В.З. Нетяженко та ін. // Адаптована клінічна настанова, заснована на доказах. — К., 2012. — 343 с.
14. Гастроезофагеальна рефлюксна хвороба / М.К. Хобзей, Н.В. Харченко, О.М. Ліщишина та ін. // Уніфікований клінічний протокол первинної та вторинної (спеціалізованої) медичної допомоги. — К., 2013. — 32 с.
15. Prevalence of Gastroesophageal Reflux Disease in Type II Diabetes Mellitus / H. Sun, L. Yi, P. Wu et al. // Gastroenterol. Res. Pract. — 2014. — Article ID 601571.
16. Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Patients with Type 2 Diabetes Mellitus / J.O. Ha, T.H. Lee, C.W. Lee et al. // Diabetes Metab. J. — 2016. — № 40 (4). — Р. 297-307.
17. Takeuchi K. Prostaglandin EP receptors and their roles in mucosal protection and ulcer healing in the gastrointestinal tract / K. Takeuchi // Adv. Clin. Chem. — 2010. — № 51. — Р. 121-44.
18. Чернышов В.А. Инсулинотерапия при сахарном диабете 2 типа: антиатерогенный или проатерогенный эффект? / В.А. Чернышов // Український терапевтичний журнал. — 2013. — № 4. — С. 5-12.
19. Сергієнко О.В. Порівняльна характеристика впливу омега-3 поліненасичених жирних кислот, статинів та їх комбінування на показники ліпідного спектра крові, судинно-тромбоцитарного гомеостазу і варіативності ритму серця у хворих на цукровий діабет 2-го типу з кардіоваскулярною автономною нейропатією / О.В. Сергієнко, С. Ажмі, О.О. Сергієнко // Міжнародний ендокринологічний журнал. — 2017. — Т. 13, № 5. — С. 315-323.
20. Дорош Е.Г. Уровень 8-изопростагландина и его взаимосвязь с метаболическими показателями у больных сахарным диабетом 2-го типа в сочетании с неалкогольной жировой болезнью печени / Е.Г. Дорош, Н.А. Кравчун // Практическая медицина. — 2013. — № 7 (76). — С. 111-116.

Вернуться к номеру